Your session is about to expire
← Back to Search
Arm I (nab-paclitaxel, gemcitabine, cisplatin) for Pancreatic Adenocarcinoma
Study Summary
"This trial is comparing the effectiveness of a 3-drug chemotherapy combination versus a 2-drug chemotherapy combination for treating pancreatic cancer that has spread and contains specific genetic mutations."
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
At how many different venues is this research endeavor being coordinated?
"The current investigation is operational in 126 diverse sites, including but not limited to Bardstown, Phoenix, and Mattoon. When considering enrollment, prioritize a site closest to your residence for convenience in commuting."
What is the current number of participants under observation in this clinical investigation?
"A total of 100 eligible individuals are sought to join this research study. Participants have the opportunity to engage in this trial at diverse locations, including Flaget Memorial Hospital located in Bardstown, Kentucky, and the Cancer Center at Saint Joseph's in Phoenix, Arizona."
Is the enrollment of participants currently ongoing for this research study?
"Indeed, data from clinicaltrials.gov affirms that this trial is actively enrolling participants. The study was initially listed on December 6th, 2023 and last revised on February 23rd, 2024. Recruitment aims to include a total of 100 individuals across 126 sites."
Share this study with friends
Copy Link
Messenger